行情

CPRX

CPRX

触媒制药公司
NASDAQ

实时行情|Nasdaq Last Sale

5.25
-0.06
-1.04%
盘后: 5.24 -0.01 -0.10% 17:40 10/18 EDT
开盘
5.28
昨收
5.30
最高
5.31
最低
5.06
成交量
86.92万
成交额
--
52周最高
7.67
52周最低
1.850
市值
5.40亿
市盈率(TTM)
-43.5993
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CPRX 新闻

  • 丰业银行:美元自1月以来的最长跌势可能持续更久
  • 新浪财经综合.53分钟前
  • 为应对脱欧协议投票 巴克莱本周日安排交易员值夜班
  • 新浪财经综合.1小时前
  • 美国对欧盟输美产品加征关税 餐饮业人士:做法很愚蠢
  • 央视.1小时前
  • 德拉吉敦促政府采取财政措施 维持贸易开放提振经济
  • 新浪财经综合.1小时前

更多

所属板块

生物技术和医学研究
-1.17%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

CPRX 简况

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
展开

Webull提供Catalyst Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。